Dellora Investments LP and its principal Kevin Pyun filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 886,630 shares of Verrica Pharmaceuticals Inc. common stock, representing 5.2% of the class as of the September 30, 2026 triggering event date.

Key Highlights

  • Aggregate beneficial ownership: Both Dellora Investments LP and Kevin Pyun each report beneficial ownership of 886,630 shares of Verrica Pharmaceuticals common stock.
  • Percent of class: The 886,630 shares represent 5.2% of the class, based on 17,178,786 shares outstanding as of July 31, 2026.
  • No sole voting or dispositive power: Both reporting persons report 0 shares with sole voting power and 0 shares with sole dispositive power; all 886,630 shares carry shared voting and shared dispositive power.
  • Triggering event date: The date of the event requiring this filing is September 30, 2026.
  • Beneficial ownership disclaimed: According to the filing, both Dellora Investments LP and Kevin Pyun "expressly disclaim beneficial ownership over any of the securities reported in this statement."
  • Shares held through funds: The filing states that Dellora Investments LP serves as investment adviser to private funds and another client, and may be deemed the beneficial owner of shares held by those funds.

Dellora Investments LP and Kevin Pyun Cross 5% Threshold in Verrica Pharmaceuticals

Dellora Investments LP, a Delaware-based registered investment adviser headquartered at 41 W Putnam Avenue, Suite 204, Greenwich, CT, and its principal Kevin Pyun jointly filed a Schedule 13G disclosing a combined position in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA), whose common stock carries a par value of $0.0001 per share and CUSIP number 92511W207. The filing was signed and dated November 16, 2026, with a triggering event date of September 30, 2026.

According to the filing, Dellora Investments LP acts as investment adviser to private funds and an additional client, collectively referred to as the "Funds." The filing states that Kevin Pyun, as Principal of Dellora Investments LP, holds "the power to exercise investment and voting discretion" over shares held by the Funds, which is why both he and the firm are listed as reporting persons with identical share counts of 886,630. The ownership percentage of 5.2% is calculated against 17,178,786 shares of common stock outstanding as of July 31, 2026, as represented by the issuer in a Form 10-Q filed with the SEC on August 6, 2026.

The filing notes that neither reporting person holds any shares with sole voting or sole dispositive power. All 886,630 shares are reported under shared voting power and shared dispositive power for both Dellora Investments LP and Kevin Pyun. The filing further states that it "shall not be construed as an admission that Dellora Investments LP or Mr. Pyun are the beneficial owner of any of the securities reported herein," reflecting the standard disclaimer under Rule 13d-4 of the Securities Exchange Act of 1934.

What Was Disclosed

Dellora Investments LP and Kevin Pyun disclosed a 5.2% ownership position, consisting of 886,630 shares of Verrica Pharmaceuticals common stock, held through funds advised by Dellora Investments LP, with all voting and dispositive power shared and none held solely.